The short-term, potential future of prostate cancer prevention

A recent article in the Journal of General Internal Medicine argues that using 5α-reductase (5-ARI) therapy (i.e., with dutasteride or finasteride) to prevent the early onset of prostate cancer is not justified by the available data. … And we entirely agree, … READ MORE …

Dutasteride delays progression of prostate cancer in REDEEM trial

The abstract for the presentation of the resulsts of the REDEEM trial (to be presented on Thursday at the Gentourinary Cancer Symposium in Orlando) was published this evening on the ASCO web site. The data show that dutasteride delayed progression of prostate cancer in a well-defined group of patients compared to placebo therapy. … READ MORE …

5-ARIs, active surveillance, and prostate cancer progression

We will presumably be at least a little wiser about this issue when data from the REDEEM trial are presented at the Genitourinary Cancers Symposium in Orlando on Thursday; however, data from Canada already suggest that 5α-reductase inhibitors (5-ARIs) affect progression of low-risk forms of prostate cancer. … READ MORE …

FDA says no to dutasteride for prostate cancer prevention

Based on the 14 to 2 “against” vote of an Oncology Drugs Advisory Committee meeting late last year, the U.S. Food & Drug Administration has rejected the application to approve dutasteride (Avodart) for prevention of prostate cancer in men at potentially elevated risk for a future postive biopsy. … READ MORE …

PSA and risk for prostate cancer in men taking dutasteride

According to further analysis of data from the REDUCE trial, “… men who are taking dutasteride can be confident that the drug does not weaken the ability of PSA to find cancer if it develops. Rather, the drug enhances the ability to find cancer if PSA levels are rising.” … READ MORE …

ODAC rejects approval of dutasteride for prostate cancer prevention

Unfortunately — but far from unexpectedly — the Oncology Drugs Advisory Committee (ODAC) to the US Food & Drug Administration today voted against the approval of durasteride for the prevention of prostate cancer in men known to be at elevated risk. … READ MORE …

FDA advisory committee to review dutasteride as chemopreventive agent

An FDA advisory committee will meet today to review data on the potential use of dutasteride for the prevention of prostate cancer. The Prostate Cancer Roundtable (including Prostate Cancer International) issued the following media release yesterday. … READ MORE …

Approval of dutasteride for reduction in risk for prostate cancer?

On December 1 this year the US Food & Drug Administration’s Oncologic Drug Advisory Committee (ODAC) will meet to hear arguments in favor of — and probably some against — the approval of dutasteride (Avodart) for “the reduction in the risk of prostate cancer in men at increased risk of developing the disease.” … READ MORE …

5-ARIs in prevention of prostate cancer — an update

The recent publication of an article on trends in the prescription of finasteride has re-stimulated the debate on the use of 5α-reductase inhibitors (5-ARIs) like finasteride and dutasteride in the prevention of prostate cancer. … READ MORE …

New drug for BPH to contain dutasteride; will affect PSA assessment

Earlier today, GlaxoSmithKline received approval from the US Food & Drug Administration to market Jalyn® — a fixed dose combination of dutasteride (Avodart) with tamulosin (Flomax) — for the treatment of benign prostatic hyperplasia (BPH). … READ MORE …

Why don’t most men consider prevention?

There are a couple of interesting new commentaries that discuss the idea of using 5α-reductase inhibitors to prevent prostate cancer (and other agents to prevent breast cancer). … READ MORE …

Data from the REDUCE trial published in NEJM

The final report from the REDUCE trial was published this morning in the New England Journal of Medicine. Most of these data were initially presented last year at the annual meeting of the American Urological Association (as reported at the time). However, there are two small problems. … READ MORE …

GSK resubmits data for approval of dutasteride to prevent prostate cancer

According to a media release earlier today, GlaxoSmithKline (GSK) has resubmitted data to the U.S. Food and Drug Administration (FDA) in support of the approval to market dutasteride (Avodart) as a drug to reduce the risk for prostate cancer among men believed to be at high risk. … READ MORE …

Who should receive a 5-ARI to prevent prostate cancer?

The “New” Prostate Cancer InfoLink has long argued that the potential of 5α-reductase inhibition (using finasteride and dutasteride) to prevent prostate cancer is under-appreciated and under-utilized. However, we also acknowledge a lack of good data to identify those patients for whom the benefits of prevention may outweigh the risks associated with the side effects of such treatment. … READ MORE …

Experts discuss prostate cancer prevention

Several experts discussed current issues related to prostate cancer prevention at the annual winter meeting of the Society for Urologic Oncology in Bethesda, MD, this week. … READ MORE …